Moderna’s Hantavirus Hype Fuels Rally Amid Setbacks

Moderna ( (MRNA) ) has risen by 14.90%. Read on to learn why.

Moderna shares climbed 14.90% over the past week as investors rushed into the stock on fresh headlines about its early-stage hantavirus vaccine research. The move followed reports of a deadly hantavirus outbreak on the MV Hondius cruise ship, which refocused attention on the virus and any potential prevention tools. Moderna confirmed it has been working with the U.S. Army Medical Research Institute of Infectious Diseases and a Vaccine Innovation Center in South Korea, though management stressed the program is still at an early research stage and far from a commercial product.

At the same time, the company’s broader pipeline sent mixed signals. Moderna and its partner Merck terminated a key Phase 2/3 trial of their personalized mRNA cancer vaccine candidate, intismeran autogene (mRNA‑4157, V940), in skin squamous cell cancer after opting not to expand the study into Phase 3. The decision removes one near‑term proof point for Moderna’s mRNA cancer ambitions in this particular tumor type and underscores how difficult and risky cancer vaccine development remains, even for a company that successfully delivered an mRNA COVID‑19 vaccine.

Despite the sharp share price rally, Wall Street remains cautious on Moderna. Analyst consensus sits at a Hold rating, and the average price target still implies double‑digit downside from recent levels, suggesting many professionals see the latest jump as driven more by headlines and long‑term potential than by immediate earnings power. For retail investors, the stock now reflects a tug‑of‑war between excitement over new infectious‑disease opportunities and lingering concerns about funding for rare outbreaks, clinical setbacks in oncology, and a long road to replacing pandemic‑era COVID revenues.